X
[{"orgOrder":0,"company":"Trigr","sponsor":"Elpiscience","pharmaFlowCategory":"D","amount":"$117.0 million","upfrontCash":"$7.0 million","newsHeadline":"TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"EUROPE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Trigr"},{"orgOrder":0,"company":"Trigr","sponsor":"Compass Therapeutics","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"EUROPE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Trigr"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Compass Therapeutics obtains global rights to TR009, a novel bispecific antibody and inhibitor of the notch pathway targeting DLL4 and VEGF-A.
Lead Product(s):
CTX-009
Therapeutic Area: Oncology
Product Name: TR009
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Compass Therapeutics
Deal Size: $14.0 million
Upfront Cash: Undisclosed
Deal Type: Acquisition
May 13, 2021
Details:
Elpiscience obtains the exclusive development and commercialization rights of TR009 for Greater China across all oncology indications and will lead the clinical development and commercialization to accelerate the path to approval of TR009 in its territory.
Lead Product(s):
Asciminib
Therapeutic Area: Oncology
Product Name: ABL001
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Elpiscience
Deal Size: $117.0 million
Upfront Cash: $7.0 million
Deal Type: Collaboration
January 20, 2021